GIVEN IMAGING ANNOUNCES RESULTS OF 2001 ANNUAL SHAREHOLDERS MEETING

                     All Proposed Resolutions Were Approved

Yoqneam, Israel, May 16, 2002 -- Given Imaging Ltd. (NASDAQ: GIVN ) announced
today the approval of all the resolutions that were proposed at its 2002 Annual
Shareholders Meeting held May 9, 2002, in Tel-Aviv. The two proposals were (a)
to re-elect all of the current directors (other than two outside directors who
were elected in December 2001 to serve a 3-year term), and (b) to re-appoint
Somekh Chaikin, a member of KPMG International, as the company's independent
auditors for the fiscal year 2002.

Shareholders holding 22,154, 642 shares, or 88.2% of the total outstanding
shares of the company, were present at the annual meeting, in person or by
proxy. On the reelection of the directors, 22,146,985 shares (99.97% of the
votes present) were voted in favor, and 7,657 shares (0.03%) were withheld. On
the re-appointment of KPMG, 22,132,382 shares (99.90%) were voted in favor,
7,560 shares (0.03%) were voted against, and there were abstentions from 14,700
shares (0.07%).

The board of directors thanks the shareholders for their participation and
continued support.

About Given Imaging

Given Imaging produces and markets the Given Diagnostic System, which features
the M2A(R) Capsule Endoscope, a fundamentally new approach to examining the
gastrointestinal tract. The system uses a disposable miniature video camera
contained in a capsule that is ingested by a patient and delivers high quality
color images in a painless and noninvasive manner. The test can be conducted
while a patient continues normal daily activities. The system received clearance
from the FDA in August 2001 and received permission to affix the CE mark in May
2001. The system is currently being marketed in 41 countries worldwide,
including the USA, Canada, Europe, Central and South America, Japan and Asia.
Many thousands of patients suffering from diseases in the small intestine such
as Crohn's, celiac disease, unexplained abdominal pain with diarrhea, polyposis,
intestinal tumors, iron deficiency anemia and obscure bleeding have already
benefited from this innovative technology. For more information, visit
http://www.givenimaging.com.

This press release contains forward-looking statements, including projections
about our business, within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. For example,
statements in the future tense, words such as "anticipates," "estimates,"
"expects," "intends," "plans," "believes," "intends" and words and terms of
similar substance used in connection with any discussion of future operating or
financial performance identify such forward-looking statements. Those
forward-looking statements are not guarantees of future performance and actual
results could differ materially from our current expectations as a result of
numerous factors, including but not limited to the following: changes in
regulatory environment, our success in implementing our sales, marketing and
manufacturing plan, protection and validity of patents and other intellectual
property rights, the impact of currency exchange rates, the effect of
competition by other companies, the outcome of future litigation, the
reimbursement policies for our product from healthcare payors, and other risks
disclosed in our filings with the U.S. Securities Exchange Commission.
                                     # # #